Newsfeeds - Spark Newswire

1 minute read

News

Albireo Announces Expanded Phase 3 Data on Bylvay and A3907 at Upcoming EASL International Liver Congress

Today, 5:49 AM

– Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters – – Bylvay patient responder data show sustained improvements in

ALBO

3 minute read

Albireo Pharma Highlights Presentation Of Data From Phase 3 PEDFIC Study

By Bill Haddad

Today, 5:49 AM

Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today presented clinical data from its Phase 3 PEDFIC 1 study and an interim data cut of the

ALBO

32 minute read

Uncategorized

Earnings Scheduled For May 6, 2021

By Benzinga Insights

Today, 5:49 AM

Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.

AAOI